Imeglimin: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{Short description|An oral antidiabetic medication}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Imeglimin.svg | |||
| image2 = | |||
}} | |||
'''Imeglimin''' is an oral antidiabetic medication used in the management of [[type 2 diabetes mellitus]]. It belongs to a novel class of oral hypoglycemic agents known as the ''glimins''. Imeglimin is unique in its mechanism of action, targeting mitochondrial bioenergetics to improve insulin sensitivity and reduce hepatic glucose production. | |||
Imeglimin' | |||
== | ==Mechanism of Action== | ||
Imeglimin | Imeglimin acts by modulating mitochondrial function, which is crucial in the pathophysiology of [[type 2 diabetes]]. It enhances insulin sensitivity in muscle tissue, reduces hepatic glucose output, and improves pancreatic beta-cell function. This multifaceted approach helps in maintaining blood glucose levels within the normal range. | ||
== | ==Pharmacokinetics== | ||
Imeglimin is administered orally and is absorbed in the gastrointestinal tract. It undergoes minimal metabolism and is primarily excreted unchanged in the urine. The pharmacokinetic profile of imeglimin supports its use as a twice-daily medication, providing sustained glucose control throughout the day. | |||
== | ==Clinical Use== | ||
Imeglimin is indicated for the treatment of type 2 diabetes, particularly in patients who have not achieved adequate glycemic control with other oral antidiabetic agents. It can be used as monotherapy or in combination with other medications such as [[metformin]], [[sulfonylureas]], or [[DPP-4 inhibitors]]. | |||
==Side Effects== | |||
Common side effects of imeglimin include gastrointestinal disturbances such as nausea and diarrhea. These side effects are generally mild and tend to resolve with continued use. Imeglimin is well-tolerated, with a safety profile similar to other oral antidiabetic agents. | |||
==Development and Approval== | |||
Imeglimin was developed by Poxel, a pharmaceutical company specializing in metabolic disorders. It has undergone extensive clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. Imeglimin has been approved for use in several countries and is undergoing further evaluation for approval in additional markets. | |||
==Related pages== | |||
* [[Type 2 diabetes mellitus]] | |||
* [[Insulin resistance]] | |||
* [[Oral hypoglycemic agents]] | |||
* [[Mitochondrial function]] | |||
[[Category:Antidiabetic drugs]] | |||
[[Category:Type 2 diabetes treatments]] | |||
Revision as of 03:54, 13 February 2025
An oral antidiabetic medication
| Imeglimin | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Imeglimin is an oral antidiabetic medication used in the management of type 2 diabetes mellitus. It belongs to a novel class of oral hypoglycemic agents known as the glimins. Imeglimin is unique in its mechanism of action, targeting mitochondrial bioenergetics to improve insulin sensitivity and reduce hepatic glucose production.
Mechanism of Action
Imeglimin acts by modulating mitochondrial function, which is crucial in the pathophysiology of type 2 diabetes. It enhances insulin sensitivity in muscle tissue, reduces hepatic glucose output, and improves pancreatic beta-cell function. This multifaceted approach helps in maintaining blood glucose levels within the normal range.
Pharmacokinetics
Imeglimin is administered orally and is absorbed in the gastrointestinal tract. It undergoes minimal metabolism and is primarily excreted unchanged in the urine. The pharmacokinetic profile of imeglimin supports its use as a twice-daily medication, providing sustained glucose control throughout the day.
Clinical Use
Imeglimin is indicated for the treatment of type 2 diabetes, particularly in patients who have not achieved adequate glycemic control with other oral antidiabetic agents. It can be used as monotherapy or in combination with other medications such as metformin, sulfonylureas, or DPP-4 inhibitors.
Side Effects
Common side effects of imeglimin include gastrointestinal disturbances such as nausea and diarrhea. These side effects are generally mild and tend to resolve with continued use. Imeglimin is well-tolerated, with a safety profile similar to other oral antidiabetic agents.
Development and Approval
Imeglimin was developed by Poxel, a pharmaceutical company specializing in metabolic disorders. It has undergone extensive clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. Imeglimin has been approved for use in several countries and is undergoing further evaluation for approval in additional markets.
